SG11201811506UA - Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof - Google Patents

Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof

Info

Publication number
SG11201811506UA
SG11201811506UA SG11201811506UA SG11201811506UA SG11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA SG 11201811506U A SG11201811506U A SG 11201811506UA
Authority
SG
Singapore
Prior art keywords
international
preparing
pct
precursors
english
Prior art date
Application number
SG11201811506UA
Other languages
English (en)
Inventor
Henry Johnson
Sean Dalziel
Dustin Mcminn
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of SG11201811506UA publication Critical patent/SG11201811506UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D301/00Preparation of oxiranes
    • C07D301/02Synthesis of the oxirane ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/38Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11201811506UA 2016-06-29 2017-06-29 Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof SG11201811506UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356178P 2016-06-29 2016-06-29
PCT/US2017/039975 WO2018005781A1 (en) 2016-06-29 2017-06-29 Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof

Publications (1)

Publication Number Publication Date
SG11201811506UA true SG11201811506UA (en) 2019-01-30

Family

ID=59351085

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811506UA SG11201811506UA (en) 2016-06-29 2017-06-29 Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof

Country Status (16)

Country Link
US (3) US10781192B2 (de)
EP (2) EP3478669B1 (de)
JP (2) JP7065044B2 (de)
KR (2) KR102524751B1 (de)
AR (1) AR108919A1 (de)
AU (1) AU2017290147B2 (de)
BR (1) BR112018077250A2 (de)
CA (1) CA3029418A1 (de)
CL (1) CL2018003873A1 (de)
CO (1) CO2019000866A2 (de)
EA (1) EA201990157A1 (de)
IL (2) IL263771B2 (de)
MX (1) MX2018016386A (de)
SG (1) SG11201811506UA (de)
TW (1) TWI751177B (de)
WO (1) WO2018005781A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478669B1 (de) * 2016-06-29 2023-08-30 Kezar Life Sciences Verfahren zur herstellung eines peptid-epoxyketon-immunproteasomhemmers

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
JP5354836B2 (ja) 2002-11-06 2013-11-27 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド プロテアソームインヒビターを使用する癌を処置するための方法および組成物
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
MY147832A (en) 2006-06-19 2013-01-31 Onyx Therapeutics Inc Compounds for enzyme inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20100088664A (ko) 2007-10-04 2010-08-10 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
CN101525370A (zh) * 2008-03-06 2009-09-09 海南建邦制药科技有限公司 一种新型高效多肽合成缩合剂
ES2617560T3 (es) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. 転移抑制のためのペプチドエポキシケトンの使用
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8609610B2 (en) 2011-02-18 2013-12-17 Trustees Of Dartmouth College Inhibitors of the trypsin-like site of the proteasome and methods of use thereof
WO2012151165A1 (en) 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
KR102054329B1 (ko) 2012-05-08 2019-12-10 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
US9187442B2 (en) 2012-06-29 2015-11-17 Nissan Chemical Industies, Ltd. Method for producing stereoselective epoxyketone compound
CA2892368A1 (en) 2012-10-11 2014-04-17 F. Hoffmann-La Roche Ag Ketoamide immunoproteasome inhibitors
JP2015536913A (ja) 2012-10-12 2015-12-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 大環状ケトアミド免疫プロテアソーム阻害薬
TW201422255A (zh) * 2012-10-24 2014-06-16 Onyx Therapeutics Inc 用於蛋白酶體抑制劑之調整釋放製劑
EP2970225B1 (de) * 2013-03-14 2018-08-15 Onyx Therapeutics, Inc. Dipeptiden und tripeptiden als epoxy ketone protease inhibitoren
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
KR102365509B1 (ko) * 2013-03-14 2022-02-21 오닉스 세라퓨틱스, 인크. 트리펩타이드 에폭시 케톤 프로테이스 억제제
CN104710507B (zh) * 2013-12-11 2018-08-14 深圳翰宇药业股份有限公司 一种卡非佐米的制备方法
CN104230857A (zh) 2014-08-19 2014-12-24 上海皓元生物医药科技有限公司 卡非佐米(Carfilzomib)的中间体化合物的制备方法及其中间体化合物
EP3478669B1 (de) * 2016-06-29 2023-08-30 Kezar Life Sciences Verfahren zur herstellung eines peptid-epoxyketon-immunproteasomhemmers

Also Published As

Publication number Publication date
IL263771A (en) 2019-01-31
EP4296257A3 (de) 2024-03-20
EP3478669B1 (de) 2023-08-30
JP2019527677A (ja) 2019-10-03
IL263771B2 (en) 2023-09-01
TW201800397A (zh) 2018-01-01
US20190194155A1 (en) 2019-06-27
TWI751177B (zh) 2022-01-01
US11976053B2 (en) 2024-05-07
US20230135100A1 (en) 2023-05-04
JP7392031B2 (ja) 2023-12-05
CO2019000866A2 (es) 2019-04-12
BR112018077250A2 (pt) 2019-04-02
EP3478669A1 (de) 2019-05-08
EA201990157A1 (ru) 2019-05-31
EP4296257A2 (de) 2023-12-27
CN109641860A (zh) 2019-04-16
US10781192B2 (en) 2020-09-22
AR108919A1 (es) 2018-10-10
KR102524751B1 (ko) 2023-04-21
US20200407334A1 (en) 2020-12-31
CA3029418A1 (en) 2018-01-04
JP2022105081A (ja) 2022-07-12
KR20230056798A (ko) 2023-04-27
CL2018003873A1 (es) 2019-06-21
JP7065044B2 (ja) 2022-05-11
KR20190025945A (ko) 2019-03-12
AU2017290147A1 (en) 2019-01-17
IL263771B1 (en) 2023-05-01
KR102571568B1 (ko) 2023-08-25
WO2018005781A1 (en) 2018-01-04
US11498907B2 (en) 2022-11-15
AU2017290147B2 (en) 2021-09-09
IL302234A (en) 2023-06-01
MX2018016386A (es) 2019-09-09

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201804934PA (en) Novel Compounds
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201807012QA (en) Acid addition salts of piperazine derivatives
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201808125RA (en) Methods for solid tumor treatment
SG11201806639VA (en) New streptococcal proteases
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201810333UA (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier